S1PR1 and multiple sclerosis: The FDA approved anti-multiple sclerosis drug fingolimod (FTY720, sphingosine-1 phosphate receptor modulator) has been shown previously to ameliorate Aβ pathology, as well as associated deficits in synaptic plasticity and memory formation in AD mice [10,37,38].